Kaleo has launched US commercial availability of EVZIO for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, according to a company announcement.
EVZIO, approved by the FDA on April 3, 2014, is the first and only naloxone product labeled for immediate administration by family members or caregivers, the company says. EVZIO is not a substitute for emergency medical care.
“Opioid overdose is a significant and growing public health concern in America and until now, there have been limited options available for the rapid administration of this potentially life-saving drug in non-healthcare settings,” said Spencer Williamson, CEO of Kaleo. “We are pleased to be able to make EVZIO available soon after receiving approval by the FDA.”
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management